Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
0(0%)
Results Posted
100%(7 trials)
Terminated
4(33%)

Phase Distribution

Ph phase_3
1
8%
Ph phase_1
5
42%
Ph not_applicable
1
8%
Ph phase_2
5
42%

Phase Distribution

5

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
1(8.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

58.3%

7 of 12 finished

Non-Completion Rate

41.7%

5 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(7)
Terminated(5)

Detailed Status

Completed7
Terminated4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
63.6%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (41.7%)
Phase 25 (41.7%)
Phase 31 (8.3%)
N/A1 (8.3%)

Trials by Status

withdrawn18%
completed758%
terminated433%

Recent Activity

0 active trials
Showing 5 of 12
completednot_applicable

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02657486
terminatedphase_3

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

NCT03773302
completedphase_2

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

NCT02159066
terminatedphase_2

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

NCT03510455
completedphase_1

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

NCT01928459
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02657486Not Applicable

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Completed
NCT03773302Phase 3

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Terminated
NCT02159066Phase 2

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Completed
NCT03510455Phase 2

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

Terminated
NCT01928459Phase 1

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Completed
NCT01697605Phase 1

A Phase I Study of Oral BGJ398 in Asian Patients

Completed
NCT02257541Phase 1

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Completed
NCT01975701Phase 2

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Completed
NCT01004224Phase 1

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Completed
NCT02160041Phase 2

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Terminated
NCT02706691Phase 2

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Terminated
NCT02312804Phase 1

Ph Ib/BGJ398/Cervix and Other Solid Tumors

Withdrawn

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12